San Diego, CA / ACCESSWIRE / November 26, 2014 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma"), (OTCQB: INNV), an emerging
commercial stage pharmaceutical company that delivers safe, innovative and
effective non-prescription over-the counter medicine and consumer care products
to improve men and women's health and vitality,
announced today that it will be presenting at the LD Micro Conference held in
Los Angeles, CA from December 2 - 4, 2014.
Event: LD Micro Conference
Location: Luxe Bel Air Hotel, Los Angeles
Date: Tuesday, December 2, 2014
Time: 2:30 PM (PT)
Management will deliver a
presentation and provide an overview of Innovus Pharma's business operations
and recent updates on the Company including commercial partnerships
signed for some of its products for distribution in 28 countries. The Company's
products include:
1. Zestra(R): clinically proven to increase desire and arousal in women
2. EjectDelay(R) :indicated for the treatment of
premature ejaculation
3. Sensum+(R): to increase penile sensitivity
4. Vesele(R):to boost sexual and cognitive health
5. Zestra Glide(R):, the only high viscosity, low osmolality
water based lubricant
In addition to the presentation, management
will be available for one-on-one meetings.
To arrange a meeting with
management, please contact Lynnette Dillen EVP and CFO at ir@innovuspharma.com.
More information on
Innovus Pharma can be found on www.innovuspharma.com; www.zestra.com, www.ejectdelay.com,
www.myvesele.com and on Innovus' Public Profile on Interlinked.com.
About Innovus Pharmaceuticals, Inc.
Headquartered
in San Diego, Innovus Pharma is an emerging leader in OTC consumer
products for men's and women's health and vitality. The Company generates revenues
from its lead products Zestra(R) clinically proven to increase arousal
and desire,EjectDelay(R) for premature ejaculation, and has
a total of five marketed products in this space, including Sensum+(R) (for sales outside the U.S. only), Zestra Glide(R) and Vesele(R) for increasing blood flow to enhance sexual and mental health.
For more information, go to www.innovuspharma.com.
Innovus Pharma's Forward-Looking Safe Harbor
Statements under the
Private Securities Litigation Reform Act, as amended: with the exception of the
historical information contained in this release, the matters described herein
contain forward-looking statements that involve risks and uncertainties that
may individually or mutually impact the matters herein described for a variety
of reasons that are outside the control of the Company, including, but not
limited to, receiving patent protection for any of its products, receiving
approval or to be compliant with the requirements of any relevant regulatory
authority relating to such products such as Zestra(R), to successfully
commercialize such products and to achieve its other development,
commercialization, financial and staffing objectives. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein. Readers are urged to read the risk factors
set forth in the Company's most recent annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from
the SEC's website or without charge from the Company.
###
Innovus Pharma
Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930
SOURCE: Innovus Pharmaceuticals, Inc.